Novartis And FDA Hit Biomarker Milestone
This article was originally published in The Pink Sheet Daily
Pilot qualifying process in renal toxicity applies to liver, heart, and other organs, Novartis execs tell “The Pink Sheet” DAILY.
You may also be interested in...
Better characterizing production, as FDA has done on the drug side, could have implications for development of follow-on products.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.